Cargando…

The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event

Hyperdiploidy (HRD) and specific immunoglobulin heavy locus (IGH) translocations are primary chromosomal abnormalities (CA) in multiple myeloma (MM). In this retrospective study of 794 MM patients we aimed to investigate clinical features and common CA including gain(1q) in separate subgroups define...

Descripción completa

Detalles Bibliográficos
Autores principales:	Locher, Maurus, Steurer, Michael, Jukic, Emina, Keller, Markus A., Fresser, Friedrich, Ruepp, Carmen, Wöll, Ewald, Verdorfer, Irmgard, Gastl, Günther, Willenbacher, Wolfgang, Weger, Roman, Nachbaur, David, Wolf, Dominik, Gunsilius, Eberhard, Zschocke, Johannes, Steiner, Normann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756645/ https://www.ncbi.nlm.nih.gov/pubmed/32936982 http://dx.doi.org/10.1002/ajh.25994

Ejemplares similares

Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma
por: Locher, Maurus, et al.
Publicado: (2022)

Clonal dynamics in a composite chronic lymphocytic leukemia and hairy cell leukemia‐variant
por: Locher, Maurus, et al.
Publicado: (2020)

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo
por: Steiner, Normann, et al.
Publicado: (2015)

Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo
por: Kern, Johann, et al.
Publicado: (2009)

Expression and release of glucose-regulated protein-78 (GRP78) in multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis
por: Steiner, Normann, et al.
Publicado: (2020)

Poor Mobilizers in Lymphoma but Not Myeloma Patients Had Significantly Poorer Progression-Free Survival after Autologous Stem Cell Transplantation: Results of a Large Retrospective, Single-Center Observational Study
por: Steiner, Normann, et al.
Publicado: (2023)

Quantification of circulating endothelial and progenitor cells: comparison of quantitative PCR and four-channel flow cytometry
por: Steurer, Michael, et al.
Publicado: (2008)

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo
por: Borjan, Bojana, et al.
Publicado: (2015)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
por: Borjan, Bojana, et al.
Publicado: (2020)

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma
por: Steiner, Normann, et al.
Publicado: (2017)

Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
por: Steiner, Normann, et al.
Publicado: (2016)

The metabolomic plasma profile of myeloma patients is considerably different from healthy subjects and reveals potential new therapeutic targets
por: Steiner, Normann, et al.
Publicado: (2018)

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies
por: Willenbacher, Wolfgang, et al.
Publicado: (2018)

Platelets and VEGF blood levels in cancer patients
por: Gunsilius, E, et al.
Publicado: (1999)

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project
por: Seeber, Andreas, et al.
Publicado: (2016)

Real world analysis of high-cut-off (HCO) hemodialysis with bortezomib-based backbone therapy in patients with multiple myeloma and acute kidney injury
por: Steiner, N., et al.
Publicado: (2020)

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics
por: Willenbacher, Ella, et al.
Publicado: (2016)

Sequence Variation within the KIV-2 Copy Number Polymorphism of the Human LPA Gene in African, Asian, and European Populations
por: Noureen, Asma, et al.
Publicado: (2015)

Response
por: Vogi, Verena, et al.
Publicado: (2022)

Levels of CEACAM6 in Peripheral Blood Are Elevated in Patients with Plasma Cell Disorders: A Potential New Diagnostic Marker and a New Therapeutic Target?
por: Steiner, N., et al.
Publicado: (2019)

Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas
por: Willenbacher, Ella, et al.
Publicado: (2020)

Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival
por: Spizzo, G, et al.
Publicado: (2003)

Lessons learned from immunoadsorption for hyperviscosity in IgM multiple myeloma—A case report
por: Gauckler, Philipp, et al.
Publicado: (2020)

P09: ATTRITION RATES IN MULTIPLE MYELOMA UNDER REAL WORLD CONDITIONS – AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY
por: Benda, MA, et al.
Publicado: (2022)

Changing Landscape in the Treatment of Adult Acute Lymphoblastic Leukemia (ALL)
por: Künz, Tina, et al.
Publicado: (2022)

Early autologous and allogeneic peripheral blood stem cell transplantation for adult patients with acute B and T cell precursor neoplasms: a 12-year single center experience
por: Steiner, Normann, et al.
Publicado: (2021)

Interesting news from the annual meeting of the American Society of Hematology 2020
por: Gunsilius, Eberhard
Publicado: (2021)

CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
por: Thangavadivel, Shanmugapriya, et al.
Publicado: (2016)

Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option
por: Bohn, Jan-Paul, et al.
Publicado: (2016)

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond
por: Strassl, Irene, et al.
Publicado: (2021)

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies
por: Pircher, Andreas, et al.
Publicado: (2016)

Complementing clinical cancer registry data with patient reported outcomes: A feasibility study on routine electronic patient‐reported outcome assessment for the Austrian Myelome Registry
por: Sztankay, Monika, et al.
Publicado: (2019)

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
por: Mair, Anna, et al.
Publicado: (2021)

Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study
por: Antlanger, Marlies, et al.
Publicado: (2018)

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)
por: Benda, Magdalena A., et al.
Publicado: (2023)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Short overview on the current standard of treatment in newly diagnosed multiple myeloma
por: Willenbacher, Ella, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_72ljdkbtpmj1v3nvnl1af64i67